Premal Thaker | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Premal Thaker | Clinical Trials | Best Researcher Award

Dr. Premal Thaker at Washington University School of Medicine, United States.

Dr. Premal Thaker is a renowned gynecologic oncologist and professor at Washington University, St. Louis. With a medical degree from Allegheny University and advanced training at MD Anderson Cancer Center, she has led impactful clinical research in ovarian and endometrial cancers 🧪. As Director of Gynecologic Oncology Clinical Research and Division Chief (2025–present), her leadership is pivotal in advancing cancer therapies. A respected speaker, grant recipient, and editorial board member 📚, Dr. Thaker has earned numerous accolades including “Best Doctors in America” and “Castle Connolly Top Doctor” 🏅. Her dedication to women’s health continues to inspire globally.

Publication Profile 

Scopus

Education

Dr. Premal Thaker’s illustrious academic journey began with a BA in Biology from Villanova University 🎓, followed by an MD from Allegheny University and an MS in Cancer Biology from the University of Texas 🧬. She completed specialized training in gynecologic oncology at MD Anderson Cancer Center and recently attended a leadership course at Harvard 🏛️. Dr. Thaker has held esteemed positions at Washington University, advancing from Assistant Professor to Division Chief of Gynecologic Oncology 👩‍⚕️. A distinguished researcher and educator, she is also the David and Lynn Mutch Distinguished Professor and Director of Clinical Research.

Awards

Dr. Premal Thaker has received numerous accolades throughout her distinguished career in gynecologic oncology 🎖️. Beginning with academic honors such as the Dean’s List and Alpha Epsilon Delta Honor Society in the early 1990s 📚, she went on to earn prestigious awards for scientific presentations and publications, including the J.G. Moore Award 🧪 and GCF/Eli Lilly Fellow Award 🧬. Recognized as one of the Best Doctors in St. Louis (2013–2025) and America (2020–2024) 👩‍⚕️, she was also named a Castle Connolly Top Doctor and Fellow of AGOS. In 2025, she joined Avant-Garde Health’s Research All-Stars.

Research Focus 

Dr. Premal Thaker’s research primarily centers on gynecologic oncology, with a strong focus on ovarian and endometrial cancers 🧫. Her work explores immune checkpoint inhibitors, personalized gene therapy, molecular profiling, and health disparities in clinical trial enrollment, particularly in Hispanic and Asian populations 🌍. She also investigates novel immunotherapy combinations, real-world treatment outcomes, and genomic biomarkers for therapy response and survival 🧪. Her multidisciplinary efforts contribute to precision medicine and the advancement of targeted therapies for women’s reproductive cancers, driving impactful, patient-centered innovations in oncology care.

Publication Top Notes

  • Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
  • OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
  • Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
  • Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
  • Diverse case series of granulomatous peritonitis mimicking advanced ovarian cancer
  • Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
  • Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis
  • Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
  • Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma
  • Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study

Hoda Salem | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Hoda Salem | Clinical Trials | Best Researcher Award

Prof. Dr. Hoda Salem, University of Tabuk, Saudi Arabia

Prof. Dr. Hoda Salem 🎓 is a distinguished clinical pharmacy expert with a Ph.D. in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. With over two decades of academic and clinical experience, she currently serves as Professor at Tabuk University, Saudi Arabia 🇸🇦. She has led numerous funded research projects, particularly in neuropharmacology and pharmacogenetics 🧬🧠. A prolific scholar, Dr. Salem has published in Q1 journals 📚 and actively mentors Ph.D. and MSc students. Her contributions extend to curriculum development, hospital training, and quality assurance in education 🌍. She’s a driving force in pharmacy education and clinical research excellence.

Publication Profile

Google Scholar

Education

Prof. Dr. Hoda Salem 🎓 earned her Bachelor’s degree in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. She continued her academic journey with a Master’s degree (M.Sc.) in Clinical Pharmacy from the same university, demonstrating early on her commitment to specialized healthcare and pharmaceutical practice 💊. Her pursuit of excellence culminated in a Ph.D. in Clinical Pharmacy in 2008 🧪, also from Tanta University. This strong academic foundation laid the groundwork for her impactful career in clinical pharmacy, education, and research, making her a respected figure in both Egyptian and international pharmaceutical education and clinical advancement.

Experience

Prof. Dr. Hoda Salem ⚕️ has made significant contributions to both scientific and clinical work in pharmacy education and healthcare. She played a pivotal role in quality assurance and accreditation by leading the self-study efforts and contributing to strategic planning at Tabuk and Al-Azhar Universities 📊📚. As a committee member, she helped supervise undergraduate examinations and mentored numerous Ph.D. and M.Sc. research projects 🎓🧬. Her clinical work includes patient counseling, drug dispensing, and providing accurate drug information to healthcare professionals at Tanta University Hospitals 💊🏥, reinforcing her commitment to enhancing both education and patient care.

Research Focus

Prof. Dr. Hoda Salem’s 🧪 research focus lies in clinical pharmacy, pharmaceutics, and neuropharmacology with a multidisciplinary approach integrating nanotechnology, drug delivery systems, and natural compounds. Her publications explore the treatment of diseases such as Alzheimer’s 🧠, Parkinson’s, ADHD, and fungal infections, along with oncology 🧬 and pharmacogenetics in breast cancer therapy. She has also worked on innovative therapies like solid lipid nanoparticles, niosomal gels, and bone marrow stem cell applications. Her clinical trials and lab studies reflect a deep commitment to therapeutic innovation, patient care, and translational research 💊🔬, bridging pharmaceutical science and clinical outcomes for better healthcare.

Publication Top Notes

Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study‏

Neuroprotective effects of phytochemicals against aluminum chloride-induced Alzheimer’s disease through ApoE4/LRP1, wnt3/β-catenin/gsk3β, and TLR4/NLRP3 pathways with physical …‏

Neuroprotective effect of morin hydrate against attention-deficit/hyperactivity disorder (ADHD) induced by MSG and/or protein malnutrition in rat pups: Effect on oxidative …‏

Autologous transplantation of CD34+ bone marrow derived mononuclear cells in management of non-reconstructable critical lower limb ischemia‏

A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major‏

The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy‏

Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients‏

Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major‏

Formulation, in-vitro and in-vivo evaluation of nystatin topical gel‏

DEVELOPMENT AND CLINICAL EVALUATION OF TOPICAL HYDROQUINONE NIOSOMAL GEL FORMULATION FOR THE TREATMENT OF MELASMA‏

Effect of oral Methyl Prednisolone on different radiological patterns of hypersensitivity pneumonitis‏

Zhumin Cao | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Zhumin Cao | Clinical Trials | Best Researcher Award

Prof. Zhumin Cao, The Seventh People’s Hospital of Chongqing, China

Prof. Zhumin Cao is a dedicated clinician and researcher in vascular diseases 🫀, with extensive experience in both basic and clinical research. He has served as a Visiting Scholar at Ajoy University Hospital 🇰🇷 and Carl Gustav Carus University Hospital 🇩🇪. Prof. Cao has led five funded research projects and published 20+ papers, including 10+ SCI articles with a cumulative impact factor of 40+ 📊. His current focus is on early intracavitary treatment of pulmonary embolism, pioneering innovations in patient care. He is also a reviewer for Angiology and Frontiers 📝.

Publication Profile

Scopus

Education

Prof. Zhumin Cao has dedicated his career to clinical and basic research in vascular diseases 🫀. He has served as a Visiting Scholar at Ajoy University Hospital in South Korea 🇰🇷 and University Hospital Carl Gustav Carus in Germany 🇩🇪. His leadership includes two provincial and three departmental-level projects 📊. He actively contributes to the scientific community as a peer reviewer for Angiology and Frontiers 📝. Prof. Cao has authored over 20 research papers, including 10+ SCI-indexed publications, with a combined impact factor of 40+, and a single article IF reaching 11.4 🌟.

Areas of Research

Prof. Zhumin Cao specializes in the field of vascular diseases 🫀, with a primary research focus on the early treatment of pulmonary embolism 🫁—a life-threatening and time-sensitive condition that poses significant challenges in clinical practice ⏱️. His work aims to improve therapeutic strategies and patient outcomes through intracavitary interventions and innovative approaches in vascular care 💉. By bridging clinical application and basic research, Prof. Cao’s studies contribute meaningfully to the development of evidence-based practices in cardiovascular medicine 🌍. His dedication supports advancements in critical care and interventional procedures that save lives every day ❤️.

Research Focus

Prof. Zhumin Cao’s research delves into the role of Interleukin-6 (IL-6) in reshaping the tumor microenvironment 🧫, a key factor in cancer progression and resistance to therapy. His work explores how IL-6-driven changes affect immune cell behavior and tumor dynamics 🧬. By understanding this cytokine’s influence, he aims to enhance the effectiveness of cancer immunotherapy 💉, offering new avenues for targeted treatments. This research bridges oncology and immunology, contributing to breakthroughs in precision medicine 🧠. Prof. Cao’s findings could lead to improved outcomes for patients battling aggressive cancers through innovative immunomodulatory strategies 🎯.

Publication Top Notes

Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy

Mert Zeytinoğlu | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Mert Zeytinoğlu | Clinical Trials | Best Researcher Award

Assoc. Prof. Dr. Mert Zeytinoğlu, Ege University Faculty of Dentistry Department of Oral and Maxillofacial Surgery, Turkey

Assoc. Prof. Dr. Mert Zeytinoğlu is a distinguished academic at Ege University, Faculty of Dentistry, specializing in Oral and Maxillofacial Surgery. With a Ph.D. from Ege University (2004), his research spans oral surgery, clinical sciences, and dental implantology. He has authored over 40 publications, holds an H-index of 3, and has led numerous projects on piezosurgery, wound healing, and dental stem cells. Known for his contributions to surgical techniques and cardiovascular safety in dental anesthesia, Dr. Zeytinoğlu actively mentors postgraduate theses and advances innovative practices in dental science.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Mert Zeytinoğlu began his academic journey at Ege University, where he earned his Bachelor’s degree in Dentistry from the Faculty of Dentistry between 1993 and 1998. His dedication to clinical sciences led him to pursue a Ph.D. in the same institution, specializing in the Department of Clinical Sciences, which he successfully completed between 1999 and 2004. 🇹🇷 Throughout his education, he demonstrated a strong commitment to advancing dental knowledge and practice in Turkey. Dr. Zeytinoğlu’s academic foundation reflects his deep passion for oral health and clinical excellence.

Experience

Assoc. Prof. Dr. Mert Zeytinoğlu has built a distinguished academic career at Ege University’s Faculty of Dentistry. Since 2015, he has been serving as an Associate Professor in the Department of Clinical Sciences, contributing significantly to academic development and clinical training. 🏫 Earlier, from 1999 to 2004, he worked as a Specialist Doctor in the Division of Clinical Sciences, specifically in the Department of Oral and Maxillofacial Surgery, where he gained extensive hands-on experience in complex dental surgeries. 🦷🔬 His academic and clinical roles reflect a deep commitment to excellence in dental education and patient care.

Awards

Assoc. Prof. Dr. Mert Zeytinoğlu received a prestigious award in 2015 for his outstanding research titled “Süt dişi- mesiodens ve daimi molar dişlerin kök hücrelerinin immünohistokimyasal ve histokimyasal yöntemlerle belirlenmesi” (Determination of Stem Cells in Primary, Mesiodens, and Permanent Molar Teeth Using Immunohistochemical and Histochemical Methods). 🧬🦷 His project earned Second Place in the Project Competition of Occupational Organizations during the İzmir Chamber of Dentists Scientific Congress and Exhibition. 🎖️ This recognition highlights his innovative approach to dental research and his contributions to scientific advancement in stem cell applications within oral health.

Research Focus

Assoc. Prof. Dr. Mert Zeytinoğlu primarily focuses on Oral and Maxillofacial Surgery 🦷 and Dental Radiology, with special expertise in the diagnosis and surgical management of jaw pathologies, including cysts, tumors, and bone defects. His research includes the use of fractal analysis 📈, peri-implant bone assessment, and management of impacted third molars, as well as multidisciplinary approaches to benign jaw tumors and dental anomalies. He also investigates the cardiovascular effects of dental anesthetics ❤️, showing interest in dental care for medically compromised patients. His work bridges clinical surgery with diagnostic innovation and patient-centered dental care.

Publication Top Notes

Oral mucosal ulceration: a manifestation of previously undiagnosed pulmonary tuberculosis

Fractal analysis for the assessment of trabecular peri-implant alveolar bone using panoramic radiographs

Effect of tube drainage compared with conventional suturing on postoperative discomfort after extraction of impacted mandibular third molars

Treatment of nonsyndromic dentigerous cysts in primary dentition

Multidisciplinary Management of Benign Jaw Tumors in

Comparison of 2 different flap techniques in the surgical removal of bilateral impacted mandibular third molars

Holter ECG assessment of the effects of three different local anesthetic solutions on cardiovascular system in the sedated dental patients with coronary artery disease/Üç …

Myofibroma of the gingiva: report of a case

Sebastian Ludwig | Clinical Trials | Best Research Article Award

Published on by Top Pharmaceutical

Sebastian Ludwig | Clinical Trials | Best Research Article Award

Assist. Prof. Dr. Sebastian Ludwig, Universität zu Köln, Germany

Dr. Sebastian Ludwig (b. 1982, Leipzig) is a distinguished gynecologist and urogynecologist, currently serving as Senior Consultant and Head of the Continence and Pelvic Floor Center at the University of Cologne. He earned his medical degree from Ruhr-University Bochum (2009) and completed his habilitation in 2023, focusing on standardization in urogynecological surgery. Dr. Ludwig is a certified clinical trial leader and expert in minimally invasive surgery. Passionate about women’s health, he plays a vital role in medical education. Married with one child, he resides in Cologne.

Publication Profile

Scopus

Education

Assist. Prof. Dr. Sebastian Ludwig 🎓 holds a Doctor of Medicine degree (magna cum laude) and has further distinguished himself by completing his habilitation, earning the venia legendi in Gynecology and Obstetrics. 🏥 His academic journey reflects a deep commitment to medical education, clinical research, and advancing women’s healthcare. With a passion for innovation and evidence-based practice, Dr. Ludwig continues to contribute significantly to his field, shaping the future of gynecological and obstetric medicine. His dedication to both patient care and academic excellence makes him a respected figure in medical education and research. 🔬📚

Experience

Assist. Prof. Dr. Sebastian Ludwig 🏥 has advanced through the medical ranks, starting as an assistant physician and progressing to Oberarzt (senior physician) at the University of Cologne’s Women’s Clinic. His expertise and leadership extend further as the Head of the Continence and Pelvic Floor Center, where he plays a pivotal role in specialized patient care and groundbreaking research. 🔬 His dedication to women’s health, particularly in urogynecology, underscores his commitment to improving treatment outcomes and advancing medical knowledge. Through his clinical and academic contributions, Dr. Ludwig continues to shape the future of gynecological care. 👨‍⚕️📚

Awards

Assist. Prof. Dr. Sebastian Ludwig 🎓 holds multiple prestigious certifications in clinical trials, urogynaecology, gynecological endoscopy, and medical research methodologies. 🏥🔬 These qualifications reflect his dedication to continuous professional development and adherence to the highest standards of research ethics. His expertise in cutting-edge medical techniques ensures optimal patient care and contributes to the advancement of gynecological science. 📚 His commitment to lifelong learning and innovation strengthens his role as a leading specialist in women’s health, making significant contributions to both clinical practice and academic research. 👨‍⚕️💡

Research Focus

Assist. Prof. Dr. Sebastian Ludwig is a dedicated researcher in minimally invasive gynecologic surgery 🏥🔬, with a primary focus on laparoscopic and open abdominal procedures for treating pelvic organ prolapse and related conditions. His work integrates advanced surgical techniques 🏗️, interdisciplinary approaches, and long-term patient outcomes 📊. His studies on uterine ligament replacement and colorectal-gynecological procedures contribute to improving women’s healthcare 👩‍⚕️💙. His research also explores trends in obstetrics 🤰📉, offering insights into evolving birth practices. With publications in top medical journals 📖🏆, Dr. Ludwig plays a crucial role in advancing female pelvic reconstructive surgery 🩺✨.

Publication Top Notes

Comparison of Open Abdominal and Laparoscopic Bilateral Uterosacral Ligament Replacement: A One-Year Follow-Up Study

Early safety and efficiency outcomes of a novel interdisciplinary laparoscopic resection rectopexy combined with sacrocolpopexy for women with obstructive defecation syndrome and pelvic organ prolapse: a single center study

Shifting Trends in Obstetrics: An 18-year Analysis of Low-risk Births at a German University Hospital

Ewa Obuchowicz | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Ewa Obuchowicz | Pharmacology | Best Researcher Award

Prof. Ewa Obuchowicz, Medical University of Silesia, Poland

Prof. Ewa Obuchowicz is the Head of the Department of Pharmacology at the Faculty of Medical Sciences in Katowice, Medical University of Silesia. She earned her M.Sc. in 1979, Ph.D. in 1985, became an Associate Professor in 2001, and a Professor in 2011. Her research focuses on psychotropic drugs, neuropeptides, cytokines, and glioblastoma therapy 🧠🔬. She has authored 89 scientific papers, with over 2,000 citations and an h-index of 20. A recipient of multiple awards 🏆, she is an esteemed member of the Polish Pharmacological Society.

Publication Profile

Scopus

Education

Prof. Ewa Obuchowicz 🎓 is a distinguished expert in pharmacology, with an impressive academic journey spanning decades. She earned her M.Sc. in 1979, followed by a Ph.D. in 1985, and attained full professorship in 2011. As the Head of the Department of Pharmacology at the Faculty of Medical Sciences in Katowice, Medical University of Silesia 🏥, she exemplifies leadership and dedication to advancing medical research. Her extensive contributions and unwavering commitment to the field make her a strong candidate for the Best Researcher Award 🏆, highlighting her impact on academia and scientific progress.

Experience 

Prof. Ewa Obuchowicz 🔬 is a renowned researcher specializing in psychotropic drug mechanisms, neuropeptides, cytokines, and glial cell protein expression. Her work delves into the complex interplay between stress, immunostimulation, and neurotrophic factors 🧠, shedding light on crucial neurological processes. Additionally, she has explored the role of the endocannabinoid system 🌿 and contributed to developing innovative adjuvant therapies for glioblastoma 🎗️. Her groundbreaking research plays a vital role in advancing medical and pharmacological sciences, solidifying her reputation as a distinguished scientist in the field. Her dedication continues to shape the future of neuropharmacology and therapeutic innovation.

Scientific Achievements

Prof. Ewa Obuchowicz 📚 has made a remarkable impact on the scientific community with 89 full-length publications, 71 of which have been cited over 2,000 times. With an h-index of 20 (Scopus) 📊, her research has gained widespread recognition. Notably, five of her papers have been cited over 100 times, highlighting their profound influence. Beyond research articles, she has contributed to authoritative pharmacology handbooks 📖, further solidifying her scholarly excellence. Her outstanding publication record and significant contributions to the field make her a deserving candidate for the award 🏆, reflecting her dedication to advancing pharmacological sciences.

Professional Memberships

Prof. Ewa Obuchowicz 🤝 is an active member of the Polish Pharmacological Society, where she contributes to professional discussions and advancements in pharmacology. Through her engagement with research organizations 🏛️, she fosters collaboration and drives progressive scientific discoveries. Her dedication to the field extends beyond her own research, as she actively participates in shaping the future of pharmacology through knowledge exchange and professional networking. By staying at the forefront of scientific discourse, she continuously enhances the impact of her work, reinforcing her role as a key contributor to the advancement of medical and pharmacological sciences.

Awards

Prof. Ewa Obuchowicz 🏅 has received prestigious recognition for her outstanding contributions to medical and pharmacological research. She has been honored with two Scientific Awards from the Minister of Health and Social Welfare 🏆 and thirteen Scientific Awards from the Rector of the Medical University of Silesia in Katowice 🎖️. These accolades reflect her dedication, innovation, and impact in the field. Her groundbreaking research and scholarly achievements continue to shape the future of pharmacology, further solidifying her candidacy for the Best Researcher Award 🏅 and reinforcing her status as a leading figure in medical science.

Research Focus

Professor Ewa Obuchowicz is a distinguished neuroscientist specializing in psychopharmacology 🧠💊, with a research focus on depression, stress, and the endocannabinoid system. Her work explores the mechanisms of antidepressants, particularly escitalopram, and their effects on neurotransmission, gene expression, and behavioral responses. She has contributed significantly to preclinical models of stress and mood disorders, investigating the role of neuropeptides, oxytocin, and the hypothalamus-pituitary-gonadal (HPG) axis 🔬📊. Additionally, her research extends to neuro-oncology, examining glioblastoma treatments. Through her studies, she aims to advance mental health therapeutics and improve understanding of stress-induced disorders.

Publication Top Notes

Escitalopram reverses anxiety-like and despair behavior and affects endocannabinoid-related genes expression in the brain of adolescent male rats subjected to early life stress

Acute Stress Affects the Relaxin/Insulin-Like Family Peptide Receptor 3 mRNA Expression in Brain of Pubertal Male Wistar Rats

How depression and antidepressant drugs affect endocannabinoid system?—review of clinical and preclinical studies

A Dot-Blot Screening for Identifying the Temozolomide-Regulated Proteins as Potential Targets for Glioma Multi-OMICS Studies

Escitalopram alters the hypothalamic OX system but does not affect its up-regulation induced by early-life stress in adult rats.

Neuropeptides as regulators of the hypothalamus-pituitary-gonadal (HPG) axis activity and their putative roles in stress-induced fertility disorders

Glucose Influences the Response of Glioblastoma Cells to Temozolomide and Dexamethasone

May application of oxytocin be relevant in the therapy of perinatal mental disorders?

Taro Shibuki | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. 🎓 He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. 🏥 His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. 🔍✨

Publication Profile

orcid

Education

Dr. Taro Shibuki 🎓 is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies 📖, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards 🏆 for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. 🚀

Research and Innovations

Dr. Taro Shibuki 🔬 is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) 📑, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach 🚀, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. 🏥

Scientific Contributions

Dr. Taro Shibuki 📚 is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics 🔍, and metabolomics 🧪 to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) 🏥 assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. 🚀

Editorial Roles

Dr. Taro Shibuki ⚕️ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) 🏥 plays a crucial role in clinical innovation. His research in drug development 💊 and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress 🔬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. 🚀

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies 🏥. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors 🏆 for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases 🔬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. 🚀

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology 🔬, with a particular focus on precision medicine 🧬, pancreatic cancer 🏥, and biliary tract cancer 🧑‍⚕️. His work involves optimizing chemotherapy 💊 and developing advanced stent deployment techniques 🏗️ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects 🧑‍🔬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics 🏥 and therapeutic strategies 💡, striving for a quantum leap in oncology 🚀 by integrating molecular profiling 🧬 and cutting-edge clinical approaches 🏥.

Publication Top Notes

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: a supplementary analysis of JCOG1407

Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Claudia Omes | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Claudia Omes | Clinical Trials | Best Researcher Award

Dr Claudia Omes, Fondazione IRCCS Policlinico San Matteo, Italy

Dr. Claudia Omes is a distinguished biologist specializing in reproductive medicine, embryology, and stem cell research. She holds multiple degrees from the University of Pavia and Milan, including a Ph.D. in Bioengineering and Bioinformatics. Dr. Omes is the Head Biologist and Lab Director at the Center for Reproductive Medicine at Policlinico “San Matteo,” Pavia, and a Contract Professor at the University of Pavia. She has contributed to pioneering research in cryopreservation, semen analysis, and stem cell biology, with multiple publications in top journals. She is an active member of ESHRE and SIERR. 🧬🔬👩‍🔬📚

Publication Profile

Orcid

Qualifications and Certifications

Dr. Claudia Omes is a distinguished expert in bioengineering and bioinformatics, holding a Ph.D. in the field, along with a Postgraduate degree in Microbiology and Virology, both achieved with high honors 🎓. She also holds multiple specialized certifications, including ISO 9001:2008 Certified Auditor in Public Health 🏅 and certifications in clinical embryology and semen analysis 🧬. Her expertise spans across bioengineering, public health, and clinical research, making her a prominent figure in the scientific community. Dr. Omes’ comprehensive academic background and specialized certifications highlight her commitment to advancing healthcare and biotechnology. 🌿💡

Research Experience

Dr. Claudia Omes is the Head Biologist and Lab Director at the Center for Reproductive Medicine of Fondazione I.R.C.C.S. Policlinico “San Matteo.” Her pioneering work in human reproduction and embryology has significantly advanced the field. She specializes in cryopreservation of spermatozoa, oocytes, and embryos, as well as in stem cell research and bone tissue engineering. Through her dedication and expertise, Dr. Omes has made notable contributions to reproductive medicine, with a focus on improving fertility treatments and tissue regeneration. Her work continues to shape the future of reproductive science. 🧬🔬🍼👩‍🔬

Awards and Recognition

Dr. Claudia Omes has earned significant recognition in the scientific community. She was awarded the Best Oral Communication in the Biological Field at the II FISSR conference in Riccione (May 24-26, 2012) 🏅. In 2011, she received the GIC Study Award from the Italian Society of Cytometry at the XXIX National Conference of Cytometry in Salerno 🎖️. Dr. Omes was also honored with the Best Poster award at the 62nd National Congress of SIAI in Verona (September 14-16, 2008) 🎨. These accomplishments showcase her excellence in the fields of cytometry and biological sciences 🌱🔬.

Research Focus

Dr. Claudia Omes focuses on reproductive biology and male infertility, exploring factors that impact sperm quality and fertility. Her research investigates the role of infections, inflammation, and biomarkers in male fertility, particularly in infertile and oncological patients. She has contributed to studies on the effects of HPV infections (HPV-51 and HPV-52) on sperm quality, the expression of miRNAs in pre-implantation embryos, and the potential of novel diagnostic approaches like calprotectin to screen for male infertility risk. Additionally, Dr. Omes has studied the effects of cancer-induced inflammation on semen quality and the application of stem cells in reproductive medicine. 🧬👨‍🔬💉

Publication Top Notes

HPV-51 or HPV-52 Infection Could Impair Sperm Quality in Infertile Patients: A Preliminary Study on Our Experience from North-Western Italy

Expression of miRNA from spent pre-implantation embryos culture media

Human Ovarian Follicular Fluid Mesenchymal Stem Cells Express Osteogenic Markers When Cultured on Bioglass 58S-Coated Titanium Scaffolds

Calprotectin as a novel diagnostic approach to screen male infertility risk: A pilot study

Male fertility preservation: is there a role for cancer-induced inflammation that affects semen quality in oncological patients?

Myeloperoxidase and lactoferrin as possible inflammatory markers of an infertility risk?

Correction: MAGIC-factor 1, a partial agonist of MET, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis (PLoS ONE (2008) 3:9 (e3223) 10.1371/journal.pone.0003223)

 

 

Dvora Joseph Davey | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dvora Joseph Davey | Clinical Trials | Best Researcher Award 

Dr Dvora Joseph Davey, University of California, Los Angeles, UCLA, South Africa

Dr. Dvora Joseph Davey is a distinguished epidemiologist with a focus on infectious diseases, particularly HIV and STIs. Holding a Ph.D. in Epidemiology from UCLA, her research, mainly in sub-Saharan Africa, aims to reduce the burden of HIV through innovative interventions. As a Principal Investigator in clinical trials, Dr. Davey has contributed significantly to global HIV prevention efforts, especially for pregnant women. She is actively involved in policy-making with groups like the WHO and NIH, shaping global health initiatives. Her leadership, extensive research, and mentorship in global health make her an exemplary figure in public health. 🌍🔬💉

Publication Profile

google scholar

scopus

orcid

Education

Dr. Dvora Joseph Davey has an impressive academic background, beginning with a B.A. in International Affairs and French from the University of Colorado, Boulder, in 1998. She went on to earn a Master of Public Health (M.P.H.) in Population and Reproductive Health Sciences from Columbia University in 2003. Dr. Davey completed her Ph.D. in Epidemiology at the University of California, Los Angeles, in 2016, followed by a fellowship in Epidemiology of HIV at the University of North Carolina in 2017. She furthered her expertise with a postdoctoral fellowship in Global HIV Prevention at UCLA in 2018. 🌍📚

Scientific Appointments

Dr. Dvora Joseph Davey has held several prestigious positions throughout her career. Currently, she serves as an Associate Professor in Infectious Diseases and Epidemiology at UCLA’s School of Medicine and School of Public Health, respectively. She also holds honorary roles at the University of Cape Town and Desmond Tutu Health Foundation. Dr. Davey’s research includes being the Principal Investigator on a study about sexual behavior and PrEP acceptability. Her past positions include HIV Director at Population Services International in Mozambique and Director at the Rwanda-Emory HIV Research Group. With her diverse roles, Dr. Davey has had a significant global impact. 🌍🩺📊

Professional Memberships

Dr. Dvora Joseph Davey has made significant contributions to the field of HIV and reproductive health, serving as an Assistant Editor for renowned journals such as AIDS, JIAS, and PloS Global Health. She is also an active member of the South African Clinical Research Association and the American Public Health Association. Her honors include invitations to present at major conferences like HIVR4P 2024 in Peru and WHO Working Group meetings. Dr. Davey has co-chaired several influential research working groups, including on PrEP in pregnancy, and received multiple awards, including UCLA’s Epidemiology Department Summer Fellowship. 🌍📚🎤

Awards

Dr. Dvora Joseph Davey is a renowned researcher whose work focuses on HIV prevention and treatment, particularly in pregnant and breastfeeding women. Her studies address key challenges in high HIV incidence communities, especially in Sub-Saharan Africa. Dr. Davey investigates Pre-exposure Prophylaxis (PrEP) access, adherence, and effectiveness among pregnant women, emphasizing the need for female-controlled HIV prevention methods during vulnerable periods. Additionally, she explores the integration of STI testing, alcohol use, and the impact of intimate partner violence on HIV risk. Her contributions significantly influence HIV-related healthcare policies, aiming to reduce transmission and improve outcomes in these populations. 👩‍🔬🌍💉

Policy Involvement

Dr. Dvora Joseph Davey has made significant contributions to national and international HIV and STI policy-making. Her leadership in key working groups, including the National PrEP and Prevention of Vertical Transmission of HIV Working Groups, as well as the World Health Organization’s Working Group on Long-Acting PrEP in pregnancy, highlights her expertise and influence. These positions enable Dr. Davey to play a pivotal role in translating scientific research into actionable policies, ensuring her work impacts not only the scientific community but also global health policies. Her efforts amplify the reach of her research, making a lasting impact on public health worldwide. 🌍🩺💉

Leadership

Dr. Dvora Joseph Davey’s leadership in managing large-scale clinical trials and mentoring emerging public health and epidemiology professionals showcases her dedication to education and capacity-building in global public health. As a recipient of the prestigious NIH/Fogarty International Research Scientist Development Award (IRSDA) and the follow-on R01 award, Dr. Davey has solidified her position as a thought leader in the field. Her commitment to fostering continuous learning and improvement within the global health community reflects her deep influence and dedication to advancing public health practices worldwide. 🎓🌍💉👩‍🔬

Ongoing Projects

Dr. Dvora Joseph Davey’s ongoing research, supported by NIH and Gilead Corporation, plays a crucial role in addressing HIV within vulnerable populations. Her work on projects like PrEP-PP and SCOPE-PP, alongside innovative initiatives such as a community-based peer-led intervention to tackle alcohol use and HIV risk in pregnant women, highlights her proactive approach to solving complex public health challenges. Dr. Davey’s research aims to create effective, targeted solutions that address the unique needs of at-risk communities, contributing significantly to advancing HIV prevention and care efforts. 💡🧑‍🔬🩺🌍

Research Focus

Dr. Dvora Joseph Davey is a prominent researcher specializing in HIV prevention, sexually transmitted infections (STIs), and maternal health. Her work focuses on pre-exposure prophylaxis (PrEP) for HIV, examining its safety and efficacy among pregnant and postpartum women. She also explores STI diagnostics, point-of-care testing, and the prevalence of curable STIs in low- and middle-income countries. Her research seeks to improve access to health interventions, particularly for vulnerable populations like men who have sex with men and transgender women. Dr. Davey’s contributions help shape public health strategies for HIV prevention and sexual health. 🦠💉

Publication Top Notes

 

Dr. Minoo Moghimi|Clinical Trials|Best Researcher Award

Published on by Top Pharmaceutical

Dr. Minoo Moghimi|Clinical Trials|Best Researcher Award

Dr. Minoo Moghimi at Mazandaran University of Medical Sciences,Iran

PROFILE  

Google scholar

 

Early Academic Pursuits 🎓

Minoo Moghimi embarked on her academic journey with a solid foundation in the National Organization for Development of Exceptional Talents, where she obtained her high school diploma in Yazd (2007-2011). This formative education laid the groundwork for her entrance into the field of pharmacy, where she pursued a PharmD at Yazd University of Medical Sciences from 2011 to 2018. Her early involvement with the faculty research committee highlighted her dedication to the field of pharmacotherapy, showcasing a keen interest in advancing pharmaceutical science right from the start.

Moghimi’s PharmD thesis focused on developing porous microencapsulated probiotics using a spray freeze drying technique. This innovative research emphasized the importance of drug formulation technology and aimed at enhancing probiotic viability. The success of this project led to a patent, marking a significant achievement in her early career and reflecting her capability to contribute meaningfully to pharmaceutical innovation.

Professional Endeavors 🏥

After completing her PharmD, Moghimi chose to channel her expertise into clinical applications by entering the Clinical Pharmacy Residency Program at Mazandaran University of Medical Sciences in 2018. This decision was driven by her passion for directly assessing drug effects in real-world patient scenarios. Throughout her residency, she demonstrated a profound dedication to clinical pharmacy, actively participating in research programs and engaging in numerous projects with a strong focus on clinical trials.

Her professional trajectory took a pivotal turn in 2020 during the COVID-19 pandemic when she contributed to the DISCOVER trial. This was a large-scale, randomized clinical trial involving over 1,000 patients, evaluating the efficacy of sofosbuvir and daclatasvir in treating hospitalized COVID-19 patients. The findings, published in the Journal of Antimicrobial Chemotherapy, were instrumental in understanding potential treatment options during the pandemic, reflecting her commitment to evidence-based clinical practice.

Moghimi’s professional expertise also extends beyond infectious diseases, as she has been involved in designing and implementing clinical trials in oncology, gynecology, and dentistry. Her diverse research portfolio underscores her adaptability and readiness to tackle multifaceted clinical challenges.

Contributions and Research Focus 📚

Minoo Moghimi’s primary research focus lies in managing chemotherapy-induced adverse effects, a critical area that significantly impacts cancer patient care. Her ongoing residency thesis, “Evaluation of the Efficacy and Safety of the Addition of Lacosamide to Duloxetine in the Treatment of Taxane-Induced Peripheral Neuropathy: A Randomized Double-Blind Placebo-Controlled Trial,” reflects this focus. Through this project, she aims to mitigate the debilitating side effects associated with chemotherapy, thus enhancing the quality of life for cancer patients.

In addition to her research in oncology, Moghimi has actively contributed to pharmacotherapy in critical care settings, clinical nutrition management, and drug-drug interaction management. Her ability to design comprehensive clinical trials is supported by her skills in clinical trial design, protocol development for critical medications, and medication reconciliation—skills that have proven vital in her multidisciplinary approach to patient care.

Moghimi’s contributions are not limited to clinical environments; she also engages in academic service. As a reviewer for respected journals like Pharmaceutical and Biomedical Research Journal (PBR) and Annals of Clinical and Medical Case Reports, she evaluates research, ensuring high standards in pharmacotherapy literature.

Accolades and Recognition 🏅

Throughout her academic and professional career, Minoo Moghimi has achieved several notable milestones. Her early achievement in patenting her thesis project during her PharmD studies reflects her commitment to innovation. During the COVID-19 pandemic, her role in the DISCOVER trial received significant recognition, as the study’s outcomes played a crucial role in informing clinical practices and treatment protocols for COVID-19 patients.

Impact and Influence 🌍

Minoo Moghimi’s research has had a tangible impact on the fields of clinical pharmacy and pharmacotherapy. Her work in chemotherapy-induced adverse effects, particularly taxane-induced peripheral neuropathy, aims to provide oncologists with better tools to manage the side effects of cancer treatments. By focusing on this critical aspect of cancer care, she is not only advancing research but also directly contributing to patient well-being, showcasing the transformative power of targeted pharmacotherapy.

Her involvement in critical care pharmacotherapy, nutrition management, and drug-drug interaction management demonstrates a holistic approach to patient care, where she considers various factors influencing therapeutic outcomes. This multidisciplinary expertise positions her as a key contributor to advancing patient-centered care in clinical settings.

Legacy and Future Contributions 🌟

Looking ahead, Minoo Moghimi aims to continue her work at the intersection of research and clinical practice. Her focus on chemotherapy-induced adverse effects, critical care, and nutrition management indicates a commitment to advancing patient care through evidence-based research. As a Board Certified Pharmacotherapy Specialist, her goal is to bridge the gap between research and clinical applications, ensuring that pharmacotherapy evolves in response to patient needs.

In the future, Moghimi plans to expand her research into novel drug therapies, aiming to develop innovative interventions for managing complex clinical conditions. Her dedication to the peer-review process reflects her intention to contribute to the scientific community by ensuring the dissemination of accurate and impactful research findings.

Skills and Technological Expertise 💻

Minoo Moghimi possesses a diverse skill set encompassing clinical trial design, research management, and critical care pharmacotherapy. Her expertise extends to protocol development for high-risk drugs, clinical nutrition, and drug-drug interaction management. In terms of technical skills, she is proficient with software like GraphPad Prism, Endnote, and MS Office—tools that are essential for managing data, conducting statistical analysis, and organizing research findings.

Research Interests and Aspirations 🔬

Her primary research interests revolve around chemotherapy-induced adverse effects, a field that holds immense potential for improving cancer care outcomes. Moghimi is also dedicated to critical care pharmacotherapy and nutrition management, fields where she hopes to make significant contributions in the future. Her aspiration is to develop strategies and guidelines that healthcare professionals can utilize to optimize treatment outcomes in complex clinical scenarios.

Conclusion 🎯

Minoo Moghimi’s journey from a dedicated pharmacy student to a Board Certified Pharmacotherapy Specialist is marked by a strong academic foundation, substantial research contributions, and a commitment to improving patient care. Her work has already left an indelible mark on the clinical pharmacy landscape, and her ongoing projects promise to further enhance therapeutic approaches in critical care and oncology. Moghimi’s career is a testament to the profound impact that dedicated research, clinical expertise, and a patient-centered approach can have in advancing healthcare.

🎓Publication 

A Narrative Review on Adverse Effects of Dasatinib With a Focus on Pharmacotherapy of Dasatinib-Induced Pulmonary Toxicities

  • Authors   :Zahra Nekoukar, Minoo Moghimi, Ebrahim Salehifar
  • Journal    :Blood Research
  • Year         :2021

Evaluation of the Effect of Sofosbuvir and Daclatasvir in Hospitalised COVID-19 Patients: A Randomized Double-Blind Clinical Trial (DISCOVER)

  • Authors   : Sara Mobarak, Mehdi Salasi, Ahmad Hormati, Javad Khodadadi, Masood Ziaee, Farshid Abedi, Azadeh Ebrahimzadeh, Zohreh Azarkar, Fariborz Mansour-Ghanaei, Farahnaz Joukar, Sara Yeganeh, Tofigh Yaghubi Kalurazi, Mohammadreza Naghipour, Zeinab Mehrabi, Amir Reza Bahadori, Shoeleh Yaghoubi, Rohollah Moslemi, Hamideh Abbaspour Kasgari, Hafez Fakheri, Minoo Moghimi, Amir Mohammad Shabani, Zahra Nekoukar, Farhang Babamahmoodi, 
  • Year         :2025

Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with moderate COVID-19, A

  • Authors   :Zahra Nekoukar , Shahram Ala, Siavash Moradi, Andrew Hill, Ali Reza Davoudi Badabi, Ahmad Alikhani, Shahriar Alian, Minoo Moghimi, Amir Mohammad Shabani, Hamideh Abbaspour Kasgari
  • Journal    :Iranian Journal of Pharmaceutical Research
  • Year         :2021

Suicide attempt using zinc phosphide rodenticide: A case report and literature review

  • Authors   :Zahra Nekoukar, Minoo Moghimi, Kimia Rasouli, Aref Hoseini, Zakaria Zakariaei, Rabeeh Tabaripour, Mahdi Fakhar, Elham Sadat Banimostafavi 
  • Journal    : Clinical case reports
  • Year         :2021

Prevalence of Thromboembolic Events, Including Venous Thromboembolism and Arterial Thrombosis, in Patients with COVID-19: A Systematic Review with Meta-Analysis

  • Authors   :Babak Bagheri, Abbas Alipour, Mojtaba Yousefi, Rozita Jalalian, Minoo Moghimi, Mahsa Mohammadi, Negar Hassanpour, Mohammadreza Iranian
  • Journal    :Tehran University of Medical Sciences
  • Year         :2023